Nintedanib, an antifibrotic agent, has been shown to prevent the progression of RA-ILD by targeting a range of kinases, including platelet-derived growth factor (PDGF) receptors α and β, various vascular endothelial growth factor (VEGF) receptor subtypes, and fibroblast growth factor (FGF) receptor types 1, 2, and 3 (13, 53). This evidence concerns the gene VEGFA and interstitial lung disease.